Prostate Cancer News on BioPortfolio

Expert Highlights NivolumabIpilimumab Potential in mCRPC

Sumit K. Subudhi MD PhD discusses the promise of the combination of nivolumab and ipilimumab in patients with metastatic castrationresistant prostate cancer and the challenges that lie ahead with this treatment approach.

SM88 Safe Active in Nonmetastatic CRPC

Benjamin A. Gartrell MD discusses the promise of SM88 in this patient population as well as other therapeutic options that are emerging for various prostate cancer subtypes.

$ARAY Ph3 Randomized Trial Data Shows SBRT has Similar Acute Safety Profile to Conventional Radiation Therapy in Patients with Localized Prostate Cancer httpswww.prnewswire.comnewsreleasesphase3randomizedtrialdatashowssbrthassimilaracutesa

$ARAY Ph3 Randomized Trial Data Shows SBRT has Similar Acute Safety Profile to Conventional Radiation Therapy in Patients with Localized Prostate Cancer httpswww.prnewswire.comnewsreleasesphase3randomizedtrialdatashowssbrthassimilaracutesafetyprofiletoco...

Lumicell Headquarters Expands Into New BostonArea Office Space

New location offers more space for future expansions and is designed to inspire innovation of Lumicell technology through further employee collaboration Lumicell Inc. an innovation leader in molecular imaging within healthc...

Darolutamide Slows Spread of CastrationResistant Prostate Cancer

TUESDAY Feb. 19 2019 Metastasisfree survival is significantly longer among men with nonmetastatic castrationresistant prostate cancer treated with darolutamide versus placebo according to a phase 3 study published online Feb. 14 in the New...

Pages